secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2022-01-24T23:59:59+00:00
Accession:  0001213900-22-003180
Event type: regulatory
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma receives Rare Pediatric Disease and Orphan Drug designations for LP-184 in ATRT
--------------------------------------------------------------------------------

- FDA grants Rare Pediatric Disease Designation and Orphan Drug Designation for LP-184 to treat atypical teratoid rhabdoid tumor (ATRT).
- LP-184 is the third Lantern program to receive Orphan Drug Designation; prior designations for pancreatic cancer and malignant glioma.
- Rare Pediatric Disease Designation may qualify Lantern for a Priority Review Voucher upon FDA approval of LP-184.
- ATRT is an aggressive CNS tumor; nearly 90% of pediatric cases involve SMARCB1 mutations, which LP-184 targets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022003180/0001213900-22-003180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000121390022003180/ea154399-8k_lantern.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-003180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer